MetaVia Inc (MTVA)
2.15
-0.17
(-7.33%)
USD |
NASDAQ |
Jan 08, 13:06
MetaVia SG&A Expense (Quarterly): 1.742M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Dermata Therapeutics Inc | 0.8243M |
| Cognition Therapeutics Inc | 3.071M |
| ZyVersa Therapeutics Inc | 1.834M |
| Cytokinetics Inc | 56.65M |
| Ocugen Inc | 6.28M |